NCT03399708View on ClinicalTrials.gov

Immune Metabolic Associations in Psoriatic Arthritis

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

June 12, 2017

Primary Completion Date

October 12, 2019

Study Completion Date

October 25, 2019

Conditions
PsoriasisPsoriatic Arthritis
Interventions
DRUG

Apremilast 30mg

Apremilast will used in line with its license. This includes the standard dose titration scheme (see section 6) and then the usual maintenance dose of 30 mg twice daily orally.

Trial Locations (1)

G31 2ER

Glasgow Royal Infirmary, Glasgow

All Listed Sponsors
lead

NHS Greater Glasgow and Clyde

OTHER

NCT03399708 - Immune Metabolic Associations in Psoriatic Arthritis | Biotech Hunter | Biotech Hunter